Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01049035 · ClinicalTrials.gov registry record · Phase 2
A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
A Phase 2 study of Meningitis and Meningococcal Infection, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 580
- Enrollment target
- 20
- Study locations
NCT01049035 is a Phase 2 study of Meningitis and Meningococcal Infection that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 580 participants, roughly in line with the 605-participant average among 7 other Meningitis trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT01049035, a Phase 2 study of Meningitis and Meningococcal Infection, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 580 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the optimal vaccination schedule for a Quadrivalent Meningococcal Polysaccharide (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (MenACYW Conjugate vaccine) in order to provide an effective protein conjugate quadrivalent meningococcal vaccine in the population with the highest incidence of disease. Objectives: * To describe the safety profile of MenACYW Conjugate vaccine administered at 5 different schedules and concomitantly with routine pediatric vaccinations. * To describe the immunogenicity profile of MenACYW Conjugate vaccine administered at 5 different schedules and concomitantly with routine pediatric vaccinations. * To describe the immunogenicity profiles of selected licensed pediatric vaccines (Pentacel, Prevnar, M-M-RII, and Varivax) when administered either concomitantly with or without MenACYW Conjugate vaccine.
Conditions Studied
Interventions
- BIOLOGICAL Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate
- BIOLOGICAL Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined)
- BIOLOGICAL M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live
- BIOLOGICAL Varicella Virus Vaccine Live
- BIOLOGICAL Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
Study Locations (20)
Kentucky
- - Bardstown
- - Crestview Hills
- - Louisville
- - Louisville
Alabama
- - Birmingham
- - Tuscaloosa
Arkansas
- - Jonesboro
- - Little Rock
California
- - Fountain Valley
- - Huntington Beach
Georgia
- - Marietta
- - Woodstock
Louisiana
- - Bossier City
North Carolina
- - Clyde
Ohio
- - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2009-12-16 |
| Est. Completion | 2012-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01049035
The ClinicalTrials.gov registry entry for NCT01049035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 580 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 605-participant average among 7 other Meningitis trials with a reported enrollment target. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Meningitis appearing as the primary indexed condition, and to 5 interventions - of which Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate is the first listed.
NCT01049035 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Kentucky, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT01049035 about?
NCT01049035 is a clinical study titled "A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers". The purpose of this study was to evaluate the optimal vaccination schedule for a Quadrivalent Meningococcal Polysaccharide (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (MenACYW Conjugate vaccine) in order to provide an effective protein conjugate quadrivalent meningococcal vaccine in the po...
What is the current status of trial NCT01049035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 580 participants. The study started on 2009-12-16. Estimated completion is 2012-02-13.
What conditions does trial NCT01049035 study?
This clinical trial studies the following conditions: Meningitis, Meningococcal Infection.
What interventions are being tested in trial NCT01049035?
The interventions under investigation include: Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate (BIOLOGICAL), Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined) (BIOLOGICAL), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live (BIOLOGICAL), Varicella Virus Vaccine Live (BIOLOGICAL), Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01049035?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01049035 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
COMPLETED · Phase 2
-
Hypovitaminosis D in Neurocritical Patients
COMPLETED · Phase 2
-
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
COMPLETED · Phase 2
-
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
COMPLETED · Phase 3
-
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years
COMPLETED · Phase 3
-
Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.